Article thumbnail

Bench-to-bedside review: Vaccine protection strategies during pandemic flu outbreaks

By Joel V Chua and Wilbur H Chen


Vaccination is the most effective means for the prevention of influenza, including pandemic strains. An ideal pandemic influenza vaccine should provide effective protection with the fewest number of doses in the shortest amount of time, and among the greatest proportion of the population. The current manufacturing processes required for embryonated chicken-egg-based influenza vaccines are limited in their ability to respond to pandemic situations - these limitations include problems with surge capacity, the need for egg-adapted strains, the possibility of contamination, and the presence of trace egg protein. Several vaccine strategies to circumvent the deficiencies intrinsic to an egg-based influenza vaccine are in various phases of development. These include the use of cell-culture-based growth systems, concomitant use of adjuvants, whole virus vaccines, recombinant protein vaccines, plasmid DNA vaccines, virus-like particle vaccines, and universal flu vaccines

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1982). Alexandrova GI, Ghendon YZ: Development of coldadapted recombinant live, attenuated infl uenza A vaccines in the U.S.A. and U.S.S.R. Antiviral Res
  2. (2009). Basser RL: Response to a monovalent 2009 infl uenza A (H1N1) vaccine.
  3. (2005). Cornblath DR: Guillain–Barré syndrome. Lancet
  4. (2006). Cox MM: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed infl uenza-virus hemagglutinin vaccine in elderly adults.
  5. (2005). Cupo A: Virus-like particle (VLP) vaccine conferred complete protection against a lethal infl uenza virus challenge. Viral Immunol
  6. (2008). Current status of live attenuated infl uenza vaccine in the United States for seasonal and pandemic infl uenza. Infl uenza Other Respi Viruses
  7. (2006). Development and evaluation of infl uenza pandemic vaccines. Lancet Infect Dis
  8. (2002). Development of serum-free media for cell growth and production of viruses/viral vaccines – safety issues of animal products used in serum-free media. Dev Biol (Basel)
  9. (1985). Dimmock NJ: Mechanism of neutralization of infl uenza virus by secretory IgA is diff erent from that of monomeric IgA or IgG. J Exp Med
  10. (2002). EL: Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived infl uenza vaccine in healthy adults, seniors, and children. Vaccine
  11. (2007). EM: Live attenuated versus inactivated infl uenza vaccine in infants and young children.
  12. (2009). Emergence and pandemic potential of swine-origin H1N1 infl uenza virus. Nature
  13. (2009). Epidemiology of fatal cases associated with pandemic H1N1 infl uenza 2009. Euro Surveill
  14. (2009). FG: ‘Prepandemic’ immunization for novel infl uenza viruses, ‘swine fl u’ vaccine, Guillain–Barré syndrome, and the detection of rare severe adverse events. J Infect Dis
  15. (2009). Finelli L: Hospitalized patients with 2009 H1N1 infl uenza in the United States, April–June
  16. (1991). GF: The geography and mortality of the 1918 infl uenza pandemic. Bull Hist Med
  17. (2005). Glezen WP: Herd immunity in adults against infl uenza-related illnesses with use of the trivalent-live attenuated infl uenza vaccine (CAIV-T) in children. Vaccine
  18. (2009). Global Advisory Committee on Vaccine Safety, World Health Organization: Statement from
  19. (2009). Global Alert and Response: Summary of Available Potency Testing Reagents for Pandemic (H1N1)
  20. (2008). H: Eff ects of adjuvants on the safety and immunogenicity of an avian infl uenza H5N1 vaccine in adults.
  21. (2009). H: Safety and immunogenicity of a subvirion inactivated infl uenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine
  22. (2009). HC: Safety and immunogenicity of multiple and higher doses of an inactivated infl uenza A/H5N1 vaccine. J Infect Dis
  23. (2009). Houn F: Considerations for licensure of infl uenza vaccines with pandemic and prepandemic indications. Curr Top Microbiol Immunol
  24. (2008). Huckriede A: Whole inactivated virus infl uenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinfl ammatory cytokines by DCs. Infl uenza Other Respi Viruses
  25. Immunogenicity and reactogenicity of infl uenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(Suppl 1):S20-S23.
  26. (2009). Immunogenicity Chua and Chen Critical Care 2010, 14:218 Page 7 of 8and adverse events of avian infl uenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis
  27. (2009). Infl uenza virus-like particle vaccines. Expert Rev Vaccines
  28. (2009). Interim analysis of pandemic infl uenza (H1N1) 2009 in Australia: surveillance trends, age of infection and eff ectiveness of seasonal vaccination. Euro Surveill
  29. (1976). JA: Guillain–Barré syndrome following vaccination in the National Infl uenza Immunization Program, United States,
  30. (2004). Kurata T: Defense mechanisms against infl uenza virus infection in the respiratory tract mucosa.
  31. (2008). Kusters I: An adjuvanted, low-dose, pandemic infl uenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
  32. (1978). Liebhaber H: Comparison of immunogenicity of a whole virion and a subunit infl uenza vaccine in adults.
  33. (2008). LR: Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) infl uenza virus. J Infect Dis
  34. (2009). McBryde ES: Avoiding Guillan–Barré syndrome following swine origin pandemic H1N1
  35. (2008). McElhaney JE: Correlates of protection: novel generations of infl uenza vaccines. Vaccine
  36. (1998). Nestruck AC, Eastwood BJ: Safety and immunogenicity of a new infl uenza vaccine grown in mammalian cell culture. Vaccine
  37. (1990). NJ: Laboratory properties of cold-adapted infl uenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 coldadapted reassortant vaccine candidates. Vaccine
  38. (2009). Novel infl uenza A(H1N1)v investigation team: Description of the early stage of pandemic (H1N1)
  39. (1979). Ogra PL: Evaluation of a neuraminidase-specifi c infl uenza A virus vaccine in children: antibody responses and eff ects on two successive outbreaks of natural infection. J Dis
  40. (1998). Osterhaus AD: Comparison of serology and reactogenicity between infl uenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig
  41. (2003). Osterhaus AD: Haemagglutination-inhibiting antibody to infl uenza virus. Dev Biol (Basel)
  42. (1979). PF: Canine kidney cell line for isolation of respiratory viruses.
  43. (1968). Plaque formation of infl uenza virus at 25°C. Nature
  44. (2009). Podda A: MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One
  45. (2009). Podda A: Safety and immunogenicity of a novel infl uenza subunit vaccine produced in mammalian cell culture. J Infect Dis
  46. (1996). Powers DC: Evaluation of a recombinant hemagglutinin expressed in insect cells as an infl uenza vaccine in young and elderly adults.
  47. (2005). Preparing for pandemic vaccination: an international policy agenda for vaccine development.
  48. (2009). Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Immune Based Ther Vaccines
  49. (1968). Protective eff ects of specifi c immunity to viral neuraminidase on infl uenza virus infection of mice. J
  50. (1989). Purifi ed infl uenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
  51. (2006). RA: Prevention and control of infl uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep
  52. (2004). RG: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of infl uenza vaccines. Lancet
  53. (2008). RT: Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other infl uenza vaccines: insights into vaccine-associated Guillain–Barré syndrome. J Infect Dis
  54. (2007). Safety and immunogenicity of a baculovirusexpressed hemagglutinin infl uenza vaccine: a randomized controlled trial. JAMA
  55. (2008). Safety and immunogenicity of an inactivated infl uenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I–II randomized clinical trial. J Infect Dis
  56. (2006). Safety and immunogenicity of an inactivated subvirion infl uenza A (H5N1) vaccine.
  57. (1998). Supplementation of conventional infl uenza A vaccine with purifi ed viral neuraminidase results in a balanced and broadened immune response. Vaccine
  58. (2000). Tamura S: Cross-protection against a lethal infl uenza virus infection by DNA vaccine to neuraminidase. Vaccine
  59. (2008). Tannock GA: Cell-based infl uenza vaccines: progress to date. Drugs
  60. (1968). TF: Replication and plaque assay of infl uenza virus in an established line of canine kidney cells. Appl Microbiol
  61. (2009). The signature features of infl uenza pandemics – implications for policy.
  62. (2009). Universal M2 ectodomain-based infl uenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines
  63. (2009). Update on infl uenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep
  64. (2002). Updating the accounts: global mortality of the 1918–1920 ‘Spanish’ infl uenza pandemic. Bull Hist Med
  65. (2000). Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine
  66. (1999). W: A universal infl uenza A vaccine based on the extracellular domain of the M2 protein. Nat Med
  67. (2003). Zahalsky AC: Infl uenza vaccination and Guillain Barré syndrome small star, fi lled. Clin Immunol
  68. (2003). Zambon MC: Safety and antigenicity of whole virus and subunit infl uenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet